QSAR‐based targeting anaplastic lymphoma kinase (ALK) variants with noncognate inhibitors in pediatric acute lymphoblastic leukemia

Human anaplastic lymphoma kinase (ALK) is a potential target for the treatment of pediatric acute lymphoblastic leukemia. However, a number of residue mutations in ALK kinase domain have been observed to cause drug resistance in pediatric acute lymphoblastic leukemia chemotherapy. Here, a chemometrics quantitative structure‐activity relationship predictor was developed using a structure‐based panel of kinase‐inhibitor activity data. The predictor was validated rigorously through internal cross‐validation and external blind test to ensure its statistical reliability, which was then used to computationally construct a systematic activity profile of 13 noncognate kinase inhibitors against both wild‐type ALK^wt and cancer‐related variants ALK^vt. It is revealed that most noncognate inhibitors exhibit weak potency on ALK^wt, but some of them are able to selectively target ALK^vt over ALK^wt. The chemometrics findings were then evaluated by using a kinase inhibition protocol; results showed that few noncognate inhibitors are 2‐ to 5‐fold higher potent against ALK variant than wild‐type kinase.     

NHC‐Pd complex based on 1,3‐bis (4‐ethoxycarbonylphenyl) imidazolium chloride: synthesis,structure and catalytic activity in the synthesis of axially chiral benzophenone hydrazone

A novel NHC–Pd complex of 1,3‐bis (4‐ethoxycarbonylphenyl) imidazolium chloride has been synthesized and characterized by ¹H NMR, ¹³C NMR, IR and X‐ray single‐crystal diffraction studies. TG analysis shows that the NHC‐Pd complex is stable under 208 °C. The catalytic activities have been explored for the synthesis of axially chiral N‐(2′‐methoxy‐1,1′‐binaphthalen‐2‐yl) benzophenone hydrazone. The result indicates that the novel NHC‐Pd complex can achieve better catalytic activity than the Pd‐phosphine catalysts in the synthesis of axially chiral N‐(2′‐methoxy‐1,1′‐binaphthalen‐2‐yl) benzophenone hydrazone.